Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.…
Vivani Medical Announces Private Placement Equity Financing
Vivani Medical (NASDAQ: VANI) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 42 employees.
The shares were at 1.140 USD on 20 November 2026, down 22.4% over 52 weeks. Its 52-week range is 0.8001 USD to 1.661 USD: the price is 31.4% below the high and 42.5% above the low.
Its market capitalisation is 102.83M USD.
Vivani Medical reports return on equity of -169.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 2.04M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 3.833 USD is 236.3% above the current price. The next earnings report is expected on 25 March 2027.